PTC Therapeutics PTCT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$2.81M— | —— | $15.9M+125% | -$64.85M-107% | $866.56M+1,415% | ||
| $15.41M+19.5% | $12.9M+16.1% | $11.11M+46.5% | $7.58M+5.0% | $7.22M+6.8% | ||
| $23.42M+26.5% | $18.52M-4.7% | $19.43M+4.8% | $18.54M+2.7% | $18.06M+4.8% | ||
| -$10K— | —— | —— | —— | $2K+100% | ||
| $305K-2.6% | $313K+2.6% | $305K+1.0% | $302K+1.0% | $299K-2.6% | ||
| -$2.64M-110% | $26.78M+44.5% | $18.53M+71.8% | $10.78M+592% | -$2.19M+80.2% | ||
| -$68.71M-164% | $108.08M+350% | -$43.21M— | —— | $18.5M+156% | ||
| -$1.18M-105% | $22.94M+1,266% | $1.68M— | —— | $16.43M— | ||
| -$2.31M— | —— | -$9.18M+45.6% | -$16.86M-3,582% | -$458K-103% | ||
| -$1.52M— | —— | -$8.14M— | —— | $7.2M+25.9% | ||
| $1.21M— | —— | $1.62M+112% | $764K-1.3% | $774K— | ||
| $1.76M-3.9% | $1.83M-8.4% | $2M+8.5% | $1.84M+3.0% | $1.79M+20.9% | ||
| —— | —— | —— | —— | -$800K+92.1% | ||
| $40.39M— | —— | $6.47M— | —— | $47.79M+217% | ||
| -$59.04M— | —— | —— | —— | $870.1M+3,000% | ||
| $1.2M-49.6% | $2.37M-31.1% | $3.45M+162% | $1.32M-23.6% | $1.72M-54.2% | ||
| $454.67M+45.6% | $312.26M+53.0% | $204.1M-61.1% | $524.83M+62.8% | $322.34M+145% | ||
| $376.36M+4.7% | $359.55M+103% | $177.2M+60.5% | $110.4M-19.3% | $136.75M-47.2% | ||
| $156K-99.6% | $34.92M-86.2% | $252.75M+9,342% | $2.68M+231% | $808K-70.4% | ||
| —— | —— | —— | —— | $70K— | ||
| -$93.74M— | $0+100% | -$289.62M+31.4% | -$422.01M-129% | -$184.36M-169% | ||
| $6.4M-89.2% | $59.39M+253% | $16.83M+1,384% | $1.13M-92.8% | $15.75M-32.2% | ||
| —— | —— | —— | —— | $6.34M+39.4% | ||
| $6.4M-97.9% | $302.5M+1,888% | $15.22M+284% | $3.96M-57.9% | $9.41M-64.5% | ||
| -$1.52M-116% | $9.8M— | —— | $13.59M+152% | $5.39M+162% | ||
| -$147.9M-147% | $312.03M+190% | -$346.77M— | —— | $700.55M+174% | ||
| $2.16M— | —— | $3.55M— | —— | $2.16M— | ||
| $4.11M-18.5% | $5.05M-17.3% | $6.1M+34.0% | $4.56M+97.0% | $2.31M-10.4% | ||
| $305K-2.6% | $313K+2.6% | $305K+1.0% | $302K+1.0% | $299K-2.6% | ||
| —— | —— | —— | —— | -$800K+92.1% | ||
| —— | —— | $8.81M— | —— | -$3.12M-184% | ||
| —— | —— | —— | —— | —— | ||
| $887K— | —— | —— | -$2.69M-19.4% | -$2.25M-122% | ||
| -$927K— | —— | —— | —— | -$77K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $2.69M0.0% | $2.69M0.0% | $2.69M0.0% | $2.69M+97.2% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$4.68M-941% | ||
| $1.59M+240% | -$1.14M+51.2% | -$2.33M-1,178% | $216K-64.6% | $611K+113% | ||
| -$1.18M-105% | $22.94M+1,266% | $1.68M— | —— | $16.43M— | ||
| $65.7M-0.2% | $65.85M+31.8% | $49.98M+0.6% | $49.67M0.0% | $49.66M-5.1% | ||
| $46.84M-41.0% | $79.41M+24.0% | $64.06M+22.9% | $52.13M+58.1% | $32.97M-37.3% | ||
| $1.76M-3.9% | $1.83M-8.4% | $2M+8.5% | $1.84M+3.0% | $1.79M+20.9% | ||
| $156K-99.6% | $34.92M-86.2% | $252.75M+9,342% | $2.68M+231% | $808K-70.4% | ||
| $376.36M+4.7% | $359.55M+103% | $177.2M+60.5% | $110.4M-19.3% | $136.75M-47.2% | ||
| —— | —— | —— | —— | $70K— | ||
| $1.55M— | —— | —— | —— | —— | ||
| $1.47M— | —— | —— | —— | —— | ||
| -$1.52M-116% | $9.8M— | —— | $13.59M+152% | $5.39M+162% | ||
| —— | $6.66M0.0% | $6.66M0.0% | $6.66M0.0% | $6.66M— | ||
| $5.29M— | —— | —— | $100K-95.4% | $2.19M— | ||
| —— | $0-100% | $381K+3,364% | $11K-97.1% | $374K+116% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $26.83M— | —— | $850K+25.7% | ||
| -$60.24M— | —— | —— | —— | $868.38M+2,671% | ||
| -$60.24M— | —— | —— | —— | $868.38M+2,671% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does PTC Therapeutics generate?
- PTC Therapeutics (PTCT) generated $704.1M in operating cash flow over the trailing twelve months.
- What is PTC Therapeutics's free cash flow?
- After $8.3M of capital expenditures, PTC Therapeutics's free cash flow was $696.9M over the trailing twelve months, up 637.5% year over year.
- Where does PTC Therapeutics's cash flow data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
